The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

All types of birth control evaluated were associated with an increased risk of any cancer, and most types of birth control were associated with an increased risk of breast cancer. Note: This ...

Outpatient management of cancer-associated PE had 30-day adverse outcome rates of 1.74% for all-cause mortality, 2.71% for major bleeding, and 1.26% for recurrent VTE. Outpatient management of ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic ...

The variability in levels of decision regret underscores the complexity of treatment decisions and the need for individualized patient support. Decision regret was a significant concern for women ...

In 37% of cases, patients said the doctor had little time to discuss patient-identified information. US cancer patients have reported positive and negative experiences when sharing patient ...

Compared with patients with undetectable ctDNA levels in this study, patients with detectable ctDNA had an increased risk of inferior EFS at day 43. Circulating tumor DNA (ctDNA) levels appear to ...

50 percent of patients with CIN3 had histopathological complete response; 63 percent had HPV16 clearance. HealthDay News — For patients with human papillomavirus (HPV) type 16 (HPV16)-positive ...

The cumulative incidence of first CRB was 9.8% at 6 months, 16.6% at 12 months, and 23.9% at 24 months. Patients with cancer demonstrated an increased risk of clinically relevant bleeding (CRB ...

Discharge readiness associated with quality of discharge education, stoma self-efficacy, age, social support, monthly income, and gender. Insufficient discharge preparation and inadequate ...

Of more than 400 phase 3 cancer trials evaluated, 32% had complete toxicity reporting, and 46% included toxicity-minimizing language. In phase 3 cancer trials, toxicity data are “often ...

AVO therapy offered sustained remission and undetectable MRD in patients with TP53 aberrations. Combination therapy with acalabrutinib, venetoclax, and obinutuzumab (AVO) is found to be highly ...